The LUNGevity report [25] on experiences of patients with lung cancer in the US with biomarker testing also highlighted challenges with interpreting the results of biomarker testing, as captured in a participant’s quote, “in my report, ...genetic findings, EGFR exon 19 deletion, no problem. The gene discussed is EGFR; the disease is lung carcinoma.